The Active Drug

When high doses of anionized albumins are administered, the uptake by the scavenger receptors in the liver and spleen becomes saturated [50]. Under these conditions, the negatively charged albumins were shown to distribute rapidly into the lymph. Furthermore, high concentrations of the protein were sustained in the lymph, which may be advantageous in relation to the antiviral effects of the drug, since the virus also resides in the lymphoid tissue [51]. 

As mentioned in Section 11.2, a special class of proteinaceous targeting constructs are those in which a therapeutic protein is used as the active drug substance. In such a preparation, the protein is redirected to the target tissue by the attachment of site-directing ligands such as those discussed in Section 11.3. For instance, interferon beta (IFN- 3) can be redirected to the liver by enz5matic desialylation in a procedure similar to that described earlier for fetuin (Section 11.3.1). The resultant asialo-IFN- 3 was found to have an in vivo anti-viral effect when tested in a hepatitis B model in athymic nude mice [54]. 

---

Prodrug. A precursor that, after administration and subsequent transformation in the body, forms the active drug. 

A seemingly complex heterocycle which on close examination is in fact a latentiated derivative of a salicylic acid shows antiinflammatory activity. It might be speculated that this compound could quite easily undergo metabolic transformation to a salicylate and that this product is in fact the active drug. Condensation of acid 134 with hydroxyl amine leads to the hydroxamic acid 135. Reaction of... 

The cl mg discovery process can be envisioned as four interconnected phases (see Figure 8.1). Generally, these are the acquisition of chemicals to be tested for biological activity, the determination of the activity of those chemicals on biological systems (pharmacodynamics), the formulation of the most active of these for therapeutic testing in humans (pharmaceutics), and the determination of adequate delivery of the active drug to diseased tissues (pharmacokinetics). Each of these collections of processes is interconnected with the others and failure in any one of them can halt the development process. It is worth considering each process separately, as well as the relationships between them. 

Figure 9.23)). The use of the pro-drug optimally produces a maximally effective concentration of the active drug in the eye, the target organ. 

Uncompetitive antagonism, form of inhibition (originally defined for enzyme kinetics) in which both the maximal asymptotic value of the response and the equilibrium dissociation constant of the activator (i.e., agonist) are reduced by the antagonist. This differs from noncompetitive antagonism where the affinity of the receptor for the activating drug is not altered. Uncompetitive effects can occur due to allosteric modulation of receptor activity by an allosteric modulator (see Chapter 6.4). 

The active drug and metabolites can be detected from the urine by thin-layer chromatography, gas-liquid chromatography, or gas chromatography-mass spectrometry. However, assays are available only at specialized centers. Treatment of acute intoxication with mescaline is virtually identical to the treatment outlined for LSD intoxication. DOM-induced vasospasm responds well to intra-arterial tolazohne or sodium nitroprusside. Major life-threatening complications of hallucinogenic amphetamine derivatives include hyperthermia, hypertension, convulsions, cardiovascular collapse, and self-inflicted trauma. 

Before a new drug can be released on the market, it must be formulated to produce a quality product that is acceptable to both regulatory bodies and patients and can be manufactured on a large scale. There are many formulation types depending on the route of administration of the active drug. 

To explore the feasibility of these polymers as a pendant delivery drug delivery system, 5-fluorouracil activated by 1,1,1,3,3,3-hexamethyl disilazane was coupled to the phosphite via the Todd reaction as shown in Scheme 2. Briefly, the polymer (PPU-7) solution in dimethylacetamide was mixed with a 1 1 v/v solution of carbon tetrachloride and methylene chloride containing 0.5 volume percent of triethylamine (TEA) as catalyst. The activated drug dissolved in methylene chloride was added slowly into the mixture and allowed to react for 48 hours at room temperature. The product was isolated by precipitation into carbon tetrachloride. 

In this type of reaction the active drug undergoes decomposition following reaction with the solvent present. Usually the solvent is water, but sometimes the reaction may involve pharmaceutical cosolvents such as ethyl alcohol or polyethylene glycol. These solvents can act as nucleophiles, attacking the electropositive centers in drug molecules. The most common solvolysis reactions encountered in pharmaceuticals are those involving labile carbonyl compounds such as esters, lactones, and lactams (Table 1). 

Parallel First-Order Reactions. In many instances, the active drug may degrade through more than one pathway ... 

If the concentration of the active drug, A, can be monitored, the composite rate constant, k = k + k2 + ky, can easily be determined from the relationship [A] = [A]0e fe where [A]0 is the initial concentration and [A] is the concentration at time t. If the concentrations of A cannot be determined because of assay difficulties, it is still possible to determine k by monitoring one of the degradation products. For example, if the concentrations of B can be assayed as a function of time, and the concentration of B at time infinity, [B], is also determined, the following relationships can be derived ... 

Another excipient used in feed additive premixes is a diluent used to dilute or standardize activity. Diluents are similar in composition to grain carriers, except the particle size is generally smaller. No attempt is made to absorb the active drug to the individual particles of the diluents. If a liquid is used it is mainly for dust control. A diluent is considered for use when the level of the active ingredient components in the premix approaches or exceeds 50% of the product or when two or more active components vary greatly from one another in density [13]. Examples of diluent materials are ground limestone, sodium sulfate, kaolin, corn cob flour, and ground oyster shells. 

There are relatively small but significant differences between active drugs and inert placebos, and these differences are independent of the type of active drug that is used. Indeed, the active drug need not even be an antidepressant. 

The more side effects that depressed patients experience on the active drug, the more they improve. 

Taken together, these data strongly support the idea that side effects lead clinical-trial patients to realize they have been given the active drug, and that this realization leads them to improve more than patients in the placebo groups. It may not be conclusive proof, but it is strong evidence. 

---